|
1
|
Lohmann CM and Solomon AR:
Clinicopathologic variants of cutaneous squamous cell carcinoma.
Adv Anat Pathol. 8:27–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alam M and Ratner D: Cutaneous
squamous-cell carcinoma. N Engl J Med. 344:975–983. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonerandi JJ, Beauvillain C, Caquant L,
Chassagne JF, Chaussade V, Clavère P, Desouches C, Garnier F,
Grolleau JL, Grossin M, et al: French Dermatology Recommendations
Association (aRED): Guidelines for the diagnosis and treatment of
cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad
Dermatol Venereol. 25:(Suppl 5). 1–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aboutalebi S and Strickland FM: Immune
protection, natural products, and skin cancer: Is there anything
new under the sun? J Drugs Dermatol. 5:512–517. 2006.PubMed/NCBI
|
|
5
|
Weinberg AS, Ogle CA and Shim EK:
Metastatic cutaneous squamous cell carcinoma: An update. Dermatol
Surg. 33:885–899. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lippman SM, Parkinson DR, Itri LM, Weber
RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IH, Gutterman JU
and Hong WK: 13-cis-retinoic acid and interferon alpha-2a:
Effective combination therapy for advanced squamous cell carcinoma
of the skin. J Natl Cancer Inst. 84:235–241. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kwa RE, Campana K and Moy RL: Biology of
cutaneous squamous cell carcinoma. J Am Acad Dermatol. 26:1–26.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tanvetyanon T, Padhya T, McCaffrey J, Kish
JA, Deconti RC, Trotti A and Rao NG: Postoperative concurrent
chemotherapy and radiotherapy for high-risk cutaneous squamous cell
carcinoma of the head and neck. Head Neck. 37:840–845. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
El-Maqsoud Abd NM and Tawfiek ER: Loss of
Maspin expression in bladder cancer: Its relationship with p53 and
clinicopathological parameters. J Egypt Natl Canc Inst. 22:1–12.
2010.PubMed/NCBI
|
|
10
|
Hopkins PC and Whisstock J: Function of
maspin. Science. 265:1893–1894. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pemberton PA, Wong DT, Gibson HL, Kiefer
MC, Fitzpatrick PA, Sager R and Barr PJ: The tumor suppressor
maspin does not undergo the stressed to relaxed transition or
inhibit trypsin-like serine proteases. Evidence that maspin is not
a protease inhibitory serpin. J Biol Chem. 270:15832–15837. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al-Ayyoubi M, Gettins PG and Volz K:
Crystal structure of human maspin, a serpin with antitumor
properties: Reactive center loop of maspin is exposed but
constrained. J Biol Chem. 279:55540–55544. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bodenstine TM, Seftor RE, Khalkhali-Ellis
Z, Seftor EA, Pemberton PA and Hendrix MJ: Maspin: Molecular
mechanisms and therapeutic implications. Cancer Metastasis Rev.
31:529–551. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor-suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai Z, Zhou Y, Lei T, Chiu JF and He QY:
Mammary serine protease inhibitor inhibits epithelial growth
factor-induced epithelial-mesenchymal transition of esophageal
carcinoma cells. Cancer. 115:36–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu S, Yu L, Cheng Z, Song W, Zhou L and
Tao Y: Expression of maspin in non-small cell lung cancer and its
relationship to vasculogenic mimicry. J Huazhong Univ Sci Technolog
Med Sci. 32:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang W, Shi HY and Zhang M: Maspin
overexpression modulates tumor cell apoptosis through the
regulation of Bcl-2 family proteins. BMC Cancer. 5:502005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Chen D, Yin S, Meng Y, Yang H,
Landis-Piwowar KR, Li Y, Sarkar FH, Reddy GP, Dou QP, et al: Maspin
augments proteasome inhibitor-induced apoptosis in prostate cancer
cells. J Cell Physiol. 212:298–306. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dzinic SH, Chen K, Thakur A, Kaplun A,
Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, et al:
Maspin expression in prostate tumor elicits host anti-tumor
immunity. Oncotarget. 5:11225–11236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reis-Filho JS, Torio B, Albergaria A and
Schmitt FC: Maspin expression in normal skin and usual cutaneous
carcinomas. Virchows Arch. 441:551–558. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abdou AG, Maraee AH, El-Monaem Shoeib MA
and Abo Saida AM: Maspin expression in epithelial skin tumours: An
immunohistochemical study. J Cutan Aesthet Surg. 4:111–117. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JH, Zhang L, Ma YW, Xiao J, Zhang Y,
Liu M and Tang H: microRNA-34a-upregulated retinoic acid-inducible
gene-I promotes apoptosis and delays cell cycle transition in
cervical cancer cells. DNA Cell Biol. 35:267–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cassarino DS, Derienzo DP and Barr RJ:
Cutaneous squamous cell carcinoma: A comprehensive
clinicopathologic classification. Part one. J Cutan Pathol.
33:191–206. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cassarino DS, Derienzo DP and Barr RJ:
Cutaneous squamous cell carcinoma: A comprehensive
clinicopathologic classification - part two. J Cutan Pathol.
33:261–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Demchenko AP: The change of cellular
membranes on apoptosis: Fluorescence detection. Exp Oncol.
34:263–268. 2012.PubMed/NCBI
|
|
27
|
Bounda GA, Zhou W, Wang DD and Yu F: Rhein
elicits in vitro cytotoxicity in primary human liver HL-7702 cells
by inducing apoptosis through mitochondria-mediated pathway. Evid
Based Complement Alternat Med. 2015:3298312015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nicholson DW and Thornberry NA: Caspases:
Killer proteases. Trends Biochem Sci. 22:299–306. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yi CH and Yuan J: The Jekyll and Hyde
functions of caspases. Dev Cell. 16:21–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarvothaman S, Undi RB, Pasupuleti SR,
Gutti U and Gutti RK: Apoptosis: Role in myeloid cell development.
Blood Res. 50:73–79. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Snigdha S, Smith ED, Prieto GA and Cotman
CW: Caspase-3 activation as a bifurcation point between plasticity
and cell death. Neurosci Bull. 28:14–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerö D and Szabó C: Poly(ADP-ribose)
polymerase: A new therapeutic target? Curr Opin Anaesthesiol.
21:111–121. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei MC, Zong WX, Cheng EH, Lindsten T,
Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and
Korsmeyer SJ: Proapoptotic BAX and BAK: A requisite gateway to
mitochondrial dysfunction and death. Science. 292:727–730. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Besbes S, Mirshahi M, Pocard M and Billard
C: New dimension in therapeutic targeting of BCL-2 family proteins.
Oncotarget. 6:12862–12871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nagata Y, Nagahisa H, Aida Y, Okutomi K,
Nagasawa T and Todokoro K: Thrombopoietin induces megakaryocyte
differentiation in hematopoietic progenitor FDC-P2 cells. J Biol
Chem. 270:19673–19675. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zou Z, Gao C, Nagaich AK, Connell T, Saito
S, Moul JW, Seth P, Appella E and Srivastava S: p53 regulates the
expression of the tumor suppressor gene maspin. J Biol Chem.
275:6051–6054. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eitel JA, Bijangi-Vishehsaraei K,
Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE and Mayo LD: PTEN
and p53 are required for hypoxia induced expression of maspin in
glioblastoma cells. Cell Cycle. 8:896–901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen WS, Yen CJ, Chen YJ, Chen JY, Wang
LY, Chiu SJ, Shih WL, Ho CY, Wei TT, Pan HL, et al: miRNA-7/21/107
contribute to HBx-induced hepatocellular carcinoma progression
through suppression of maspin. Oncotarget. 6:25962–25974. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang
C and Wu M: Decreased levels of miR-224 and the passenger strand of
miR-221 increase MBD2, suppressing maspin and promoting colorectal
tumor growth and metastasis in mice. Gastroenterology. 145:853–864,
e859. 2013. View Article : Google Scholar : PubMed/NCBI
|
